Tolerability and safety of study treatment will be evaluated throughout the study by collection of clinical and laboratory data. In Phase 2, antitumor response will be assessed according to standard Response Evaluation Criteria in Solid Tumors (RECIST v1.1) using computed tomography (CT) or magnetic resonance imaging (MRI) scans or assessed using another reliable method of disease evaluation appropriate for the tumor type.